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Abstract
Background: There is a continuing debate on the desirability of informing patients with cancer and thereby
involving them in treatment decisions. On the one hand, information uptake may be hampered, and additional
stress could be inflicted by involving these patients. On the other hand, even patients with advanced cancer desire
information on risks and prognosis. To settle the debate, a decision aid will be developed and presented to
patients with advanced disease at the point of decision making. The aid is used to assess the amount of
information desired. Factors related to information desire are explored, as well as the ability of the medical
oncologist to judge the patient’s information desire. The effects of the information on patient well-being are
assessed by comparing the decision aid group with a usual care group.
Methods/Design: This study is a randomized controlled trial of patients with advanced colorectal, breast, or
ovarian cancer who have started treatment with first-line palliative chemotherapy. The trial will consist of 100
patients in the decision aid group and 70 patients in the usual care group. To collect complete data of 170
patients, 246 patients will be approached for the study. Patients will complete a baseline questionnaire on
sociodemographic data, well-being measures, and psychological measures, believed to predict information desire.
The medical oncologist will judge the patient’s information desire. After disease progression is diagnosed, the
medical oncologist offers the choice between second-line palliative chemotherapy plus best supportive care (BSC)
and BSC alone. Randomization will take place to determine whether patients will receive usual care (n = 70) or
usual care and the decision aid (n = 100). The aid offers information about the potential risks and benefits of both
treatment options, in terms of adverse events, tumour response, and survival. Patients decide for each item
whether they desire the information or not. Two follow-up questionnaires will evaluate the effect of the decision
aid.
Discussion: This study attempts to settle the debate on the desirability of informing patients with cancer. In
contrast to several earlier studies, we will actually deliver information on treatment options to patients at the point
of decision making.
Trial registration: Netherlands Trial Register (NTR): NTR1113
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Good clinical practice encompasses optimal providing of
information to patients. However, as yet the debate
about the desirability of informing patients with cancer
and thereby involving them in their own care process
has not been resolved. On the one hand, it has been
shown that patients with more severe disease may
become emotionally unstable and tend to leave decision
making to their physician [1-3]. Furthermore, patients
with cancer may sometimes deny their illness [4]. In
short, patients may wish ‘not to know’. All these factors
hamper the uptake of information. It is conceivable that
additional stress could be inflicted upon patients by
involving them in decisions which are complex, emo-
tionally hot, with high personal stakes and have to be
taken under time pressure. These circumstances are
unfavourable for rational decision making [5]. Taken
these arguments together, the positive effects of inform-
ing cancer patients with relevant information for treat-
ment decision making can be questioned.
On the other hand, cancer patients desire to be
informed about risks and prognosis. A systematic review
of Gaston et al. (2005) [6] showed that almost all cancer
patients wish to be fully informed, regardless of the
stage of their disease. Studies using the questionnaire
that was developed by Cassileth et al.1 9 8 0[ 7 ]s h o w e d
that 83%-92% of advanced cancer patients wanted as
much information as possible, whether good or bad
[7-10]. Hagerty et al. 2004 [11] more specifically
explored the desire for prognostic information and
showed that over 80% of advanced cancer patients
wanted to know the longest time to live with treatment,
5-year survival rates, and average survival. Unlike the
aforementioned studies that probed preferences, Elit
et al. [12] actually delivered information to patients with
advanced gynaecological cancer. A decision instrument
was used to present information on two chemothera-
peutic treatment options and their potential risks and
benefits. Survival information was desired by and pro-
vided to 92% of the women. However, these patients
were asked to make a hypothetical decision, since the
treatment choice would not actually be carried out. In
the present study, we will assess patients’ information
desire by offering information in a decision aid at the
point of decision making. The treatment choice of
patients will actually be carried out.
The amount of information desired may be predicted
by a number of patient-related and disease-related fac-
tors. It is known that a higher amount of information is
preferred by patients who are younger, better educated,
have received the diagnosis more recently, and are in a
less advanced stage of the disease [7,9,10,13]. In our
study, where we actually deliver information using a
decision aid, we will examine how various sociodemo-
graphic, medical, and psychological characteristics of the
patient are related to the patient’s information desire.
Current practice of information giving by physicians
was investigated by studies in Australia [14,15] and the
Netherlands [16], by audio taping the first consult of
incurable cancer patients with their oncologists. In both
Australia and the Netherlands, the majority of patients
were informed about the absence of cure (75% and 84%,
respectively). However, information about life expec-
tancy or prognosis was communicated to only 58% and
39% of Australian and Dutch patients, respectively. Only
half of the patients in both countries were informed
about the alternative to active treatment, best supportive
care (BSC). When BSC was mentioned in the Netherlands,
half of the time it was mentioned in a single sentence.
Obviously, not all information issues were covered in
every first consultation. The oncologists may have
intuitively tailored the amount and content of informa-
tion to the individual patient. However, whereas stu-
dies have indicated that over 80% of patients desire all
information, the percentages of Australian and Dutch
patients receiving all information were noticeably
lower. This raises the question whether the oncologists
may have underestimated the amount of information
desired by their patients. In the present study, we will
assess whether medical oncologists are able to judge
their patients’ information desire.
A main concern of physicians is that the provision of
prognostic information to seriously ill patients may pro-
voke patient anxiety. Our target population of patients
with incurable disease may be particularly anxiety-
prone. To address this issue, the effects of the decision
aid are evaluated by comparing the decision aid group
to a usual care group. The evaluation will examine
effects on patient well-being, information and decision
related outcomes, and treatment choice.
In conclusion, we aim to settle the debate on the
desirability of informing patients with cancer by devel-
oping a decision aid to assess the amount of information
desired by patients with advanced cancer at the point of
decision making. The study population will consist of
patients with advanced colorectal, breast, or ovarian
cancer who are treated with first-line chemotherapy and
upon disease progression will face the choice between
two equivalent treatment options. These patients can
decide to have second-line chemotherapy in combina-
tion with BSC, or they can refrain from further
chemotherapy and opt for BSC alone. Second-line
chemotherapy may induce tumour response and prolong
survival, but also entails a risk of serious adverse events.
Our research questions are: 1a) Do these patients want
to be informed about the treatment options, and
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determine whether or not these patients want to be
informed? 2) Can the medical oncologist judge whether
or not the patient wants the risk information? 3) What
is the effect of the decision aid on patient outcomes
(well-being, information and decision related outcomes,
treatment choice) compared to usual care?
Methods/Design
Patients
In 11 hospitals in the Netherlands, all patients with
advanced colorectal, breast, or ovarian cancer who have
started treatment with first-line palliative chemotherapy
and upon disease progression will be faced by the choice
regarding second-line palliative chemotherapy will be
included. Exclusion criteria are labile personality struc-
ture, as assessed by the physicians, a Karnofsky perfor-
mance score lower than 60, and insufficient knowledge
of the Dutch language. The study has been approved by
the research ethics committees of all participating
hospitals.
Procedure
The medical oncologist, or a nurse who first consulted
the medical oncologist, will inform eligible patients in a
general way that this study focuses on ‘how to involve
the opinion of patients in the treatment’.N e x t ,h eo r
she will ask whether the researcher can contact the
patient by phone about this study. The oncologist or
nurse is instructed not to discuss that survival informa-
tion can be provided in the study, in order not to lose
patients not desiring such information. After the visit of
the patient, the oncologist fills in the medical history on
the inclusion form. He or she also makes a judgment
whether or not the patient will desire information about
adverse events, tumour response, and median survival
that will be offered in the interview (research question 2).
In the phone call, patients are explained that data are
collected by means of three questionnaires and possibly
an interview. All patients who agree to participate will
provide written informed consent.
Patients will be sent a baseline questionnaire (t1) to col-
lect sociodemographic data, well-being measures, and
measures that predict information desire. When tumour
progression is diagnosed, second-line chemotherapy will
be offered by the oncologist and randomization will be
performed. Patients in the usual care group will receive
information about the treatment choice from their oncolo-
gist. In the intervention group, patients will receive the
same information, and will in addition be offered informa-
tion in an interview using a decision aid. At the moment
of disease progression, the medical oncologist is asked to
estimate patient survival, because this is expected to be
associated with the patient’s information desire.
To evaluate the effect of the decision aid, two follow-
up questionnaires will be sent to the patients, one week
(t2) and eight weeks (t3) after the treatment choice,
before the first evaluation of chemotherapy. Figure 1
displays the complete procedure.
Randomization
Randomization will be performed to determine whether
the patient will receive usual care (n = 70) or usual care
plus the decision aid (n = 100). To accomplish this, a
computer generated randomization list is prepared that
is stratified by hospital, using a block size of 3. Each
participating hospital will receive three sets of sealed
envelopes, related to colorectal, breast, and ovarian
cancer patients. When disease progression is diagnosed
by the oncologist, a nurse will perform the randomiza-
tion by opening the appropriate envelope.
Development of the decision aids
Decision aids on second-line treatment options for
patients with advanced colorectal, breast, and ovarian
cancer are developed. In this decision aid, the two treat-
ment options are explained. Next, an overview of the
potential risks and benefits of the two treatment options
is presented. The information on risks and benefits is
obtained from systematic reviews of the literature for
each tumour type. Risk information includes the occur-
r e n c eo fs e r i o u sa d v e r s ee v e n t s ,w h i c ha r ed e f i n e da s
grade 3 or 4 according to the Common Terminology
Criteria for Adverse Events v3.0 (CTCAE) and are pre-
sented as adverse events that can be life threatening,
can result in a hospital admission or prolongation of
existing hospitalization, or can lead to a persistent or
significant disability/incapacity. Tumour response is
defined according to WHO or RECIST criteria and clas-
sified into overall response (complete or partial
response), stable disease, and progressive disease. For
both serious adverse events and tumour response, the
probability that outcomes occur is presented in frequen-
cies (n of 100 patients) and by means of pie charts,
using a mixed frame, e.g. ‘22 out of 100 patients will
experience severe diarrhoea, 78 out of 100 patients will
not experience severe diarrhoea’. Information on survi-
val is presented in the format of median survival.
Interview
T h ed e c i s i o na i di sd e l i v e r e db yan u r s eo rb yt h e
researcher. First, the two treatment options are
explained. Then, to familiarize patients with the general
issue of trade-offs between benefits and risks, an exam-
ple of a risky two-attribute non-cancer related choice is
presented. After this example, the interviewer explains
the first item of the decision aid regarding serious
adverse events. This explanation includes the definition
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in the type of information that can be expected. Next,
the patient is asked whether or not the information on
serious adverse events is desired. The same procedure is
followed for the other items on tumour response and
survival. At the end of the interview, the patient can
take home a brochure with information, tailored to the
information desire of the patient. The interviewer fills in
a questionnaire to register information desire and to
provide a short evaluation of the interview.
initial invitation by the oncologist or a nurse 
 -medical history 
 -substitute judgment of information desire 
assessed for eligibility by medical oncologist
phone call by the researcher  
followed by written informed consent 
baseline questionnaire (t1) 
- sociodemographic data 
- well-being measures 
- predictors of information desire 
diagnosis of progression: treatment choice  
- estimate of survival by oncologist 
randomization
usual care  
(n=70) 
usual care  
and interview using the decision aid  
(n=100)
exclusion criteria 
labile personality structure 
Karnofsky performance score < 60 
insufficient knowledge of the Dutch language 
follow-up questionnaire after one week (t2) 
- well-being measures  
- other effects on coping, information, 
knowledge, decision, and treatment attitudes 
follow-up questionnaire after eight weeks (t3) 
- well-being measures 
- other effects on coping, information, 
knowledge, decision, and treatment attitudes 
Figure 1 Overview of study procedure.
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Table 1 shows an overview of all outcome measures and
the moment of measurement.
Sociodemographic variables and medical history
Self-report data are collected at t1 on demographic vari-
ables (age, marital status, having (grand)children, being
religious, working status, and education) and on pre-
vious chemotherapy, including experienced benefits and
adverse events, and time since last chemotherapy.
Tumour and treatment characteristics such as primary
tumour site, previous chemotherapy, and time since
diagnosis are filled in on the inclusion form by the med-
ical oncologist. At the moment of disease progression,
the medical oncologist is asked to estimate patient survi-
val. Answer possibilities are 3-6 months, 6-9 months, 9-
12 months, and more than 12 months.
Well-being
Patients rate their general health in the previous week
on an 11-point rating scale (0-10). Anxiety and depres-
sion are assessed with the Hospital Anxiety and Depres-
sion Scale (HADS) [17]. Cancer worries are rated with
three questions, adapted from Lerman et al. [18] and
Stefanek et al. [19]: ‘Did you think of cancer last week?’,
‘Did these thoughts affect your mood?’,a n d‘Did these
thoughts affect your daily activities?’. Health-related
quality of life is assessed by means of the EORTC QLQ-
C15 PAL quality of life questionnaire for cancer patients
in palliative care [20].
Coping
Coping with cancer is assessed with the Mental Adjust-
ment to Cancer scale [21]. Three coping strategies are
assessed: helplessness/hopelessness, avoidance, and
fighting spirit. The patient’s decision style is assessed
with The Michigan Assessment of Decision Style
(MADS) [22]. The MADS covers (1) avoidance (four
items, e.g. ‘I prefer not knowing the possibility that
unexpected things could happen to me’); (2) deferring
responsibility (three items, e.g. ‘I would follow the
recommendations of my physician’); (3) information
seeking (four items, e.g. ‘I would spend as much time as
I could gathering information’); and (4) deliberation
(five items, e.g. ‘I would carefully consider the risks of
each option as I was making a choice’). The general par-
ticipation preference at baseline is measured with the
two decision-making items from the Problem-Solving
Decision-Making Scale [23]. The questions are as fol-
lows: ‘When the risks and benefits of the treatment
options are known to you, (1) who decides how accepta-
ble those risks and benefits are for you and (2) who
decides what treatment should be selected?’.A n s w e r s
range from ‘only the physician’ to ‘only me’. Perceived
participation is assessed by the same questions in past
tense, after the decision is made. Perceived involvement
is measured by asking patients whether they felt they
were offered a choice between BSC plus chemotherapy
and BSC alone [24]. In addition, patients are asked
whether their opinion regarding the treatment mattered.
Both questions use a yes/no response. Death avoidance
will be measured by means of the Death Avoidance
Scale, which was adapted by Kaplowitz et al.2 0 0 2[ 2 5 ]
from the original Death Acceptance Scale developed by
Klug and Sinha (1987) [26]. The two items are as fol-
lows: ‘I avoid discussing death when the occasion pre-
sents itself’ and ‘Im a k eac o n s c i o u se f f o r tt oa v o i d
dwelling on thoughts of death’, and are measured on a
5-point scale (1 = strongly disagree, 5 = strongly agree).
Information
The preferred amount of information is measured on a
11-point scale ranging from 0 (I want to know nothing
about the illness and its treatment) to 10 (I want to
know everything there is to know about the illness and
its treatment) [8]. The amount of information received
about the treatment choice is measured on a 7-point
scale ranging from 1 (I received way too little informa-
tion), 4 (I received exactly enough information), to 7 (I
received way too much information). Information
received during the consultation with the oncologist,
regarding adverse events, tumour response, and survival,
is assessed using a yes/no response. Whether patients
received any undesired information is asked with a
question using a yes/no response. The key variable
information desire is described under ‘Interview’ above.
Satisfaction with the quality of information is asked with
three questions related to information on adverse
events, tumour response, and survival. Responses are on
a 6-point scale ranging from 1 (not satisfied) to 6 (very
much satisfied). The balanced presentation of informa-
tion is evaluated on a 5-point scale from 1 (clearly in
favour of chemotherapy plus BSC), 3 (balanced), to 5
(clearly in favour of BSC alone). Six questions are asked
about unpleasant, shocking, frightening, and threatening
experiences with the information received, measured on
a 5-point scale from 1 (no negative experience) to 5
(very negative experience). Numeracy, i.e. the ability to
handle basic probability concepts, needed for the inter-
pretation of risk information, is measured by the Subjec-
tive Numeracy Scale (SNS) [27].
Knowledge
Patients rate their own knowledge (subjective knowl-
edge) on cancer treatments with a single question on a
10-point scale ranging from 1 (very bad) to 10 (excel-
lent). Two questions are asked to assess the subjective
knowledge with respect to risks and benefits of treat-
ment options on a 10-point scale. Objective knowledge
will be measured with a questionnaire containing five
statements related to the two options BSC plus che-
motherapy and BSC alone. These statements have to be
judged as right or wrong. Subjective risk perception is
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Subject Questionnaire Inclusion T1 Disease
progression
Interview T2 T3
Sociodemographic characteristics x
Previous chemotherapy x
OUTCOME MEASURES & PREDICTORS OF INFORMATION DESIRE
Well-being General Health x x x
Anxiety & Depression Hospital Anxiety and Depression
Scale
xx x
Cancer Worries Adapted Lerman’s Cancer Worry
Scale
xx x
Health-related quality of life EORTC QLQ-C15 PAL x x x
Coping Helpless/Hopeless, Avoidance,
Fighting Spirit
Mental Adjustment to Cancer
Scale
xx x
Decision Styles Michigan Assessment of
Decision Style
x
Participation Preferences Problem-Solving Decision-
Making Scale
x
Perceived participation Problem-Solving Decision-
Making Scale
xx
Perceived involvement Whelan x x
Death avoidance Death Avoidance Scale x
Information Preference for information x
Amount of information x x x
Information from oncologist x
Undesired information x
Information desire x
Satisfaction with quality of
information
xx
Balanced presentation of information x
Evaluation of information xx
Numeracy Subjective Numeracy Scale x
Knowledge General subjective knowledge x
Treatment subjective knowledge x
Objective knowledge x
Subjective risk x
Objective risk x
Decision Decision satisfaction-uncertainty Decision evaluation scale x x
Decision control Decision evaluation scale x x
Weighing pros and cons Decision evaluation scale x x
Treatment choice xx
Strength of treatment preference xx
Treatment
attitudes
Valuations xx
Treatment satisfaction x
Preferences for Quality/Quantity of
Life
QQ Questionnaire x
PHYSICIAN’S QUESTIONS
Medical history Tumour and treatment characteristics x
Substitute
judgment
Substitute judgment of information
desire
x
Prognosis Estimate of survival x
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cing a serious adverse event from 1 (very high) to 5
(very low), the chance that stable disease or a response
will be achieved by BSC plus chemotherapy, as opposed
to BSC alone from 1 (much higher) to 7 (much lower),
and the chance of experiencing pain on treatment with
BSC plus chemotherapy, as opposed to BSC alone from
1 (much higher) to 7 (much lower). Objective risk per-
ception is asked for the chance of experiencing severe
diarrhoea, and the chance of achieving a response.
Patients are asked to give a risk estimate for these two
outcomes in a range from 0% to 100%.
Decision
Satisfaction and uncertainty regarding the choice
between BSC plus chemotherapy and BSC alone are
assessed using five items [28], e.g. ‘If i n di th a r dt o
make this choice’, ‘I am satisfied with my decision’, mea-
sured on a 5-point scale (1 = strongly disagree, 5 =
strongly agree). Patients are also asked about their feel-
ing of control regarding this treatment choice using five
items [28], e.g. ‘This decision is made without me’, ‘I
feel pressure from others in making this choice’, mea-
sured on a 5-point scale (1 = strongly disagree, 5 =
strongly agree). Weighing of pros and cons of the treat-
ment options was asked with a single question ‘I
weighed the pros and cons’, on a 5-point scale (1 =
strongly disagree, 5 = strongly agree). Treatment choice
is collected by asking which treatment patients prefer.
Response options are: BSC plus chemotherapy, BSC
alone, don’t know. Strength of treatment preference (for
one or the other option) is asked on a 4-point Likert
scale ranging from 1 (weak preference) to 4 (very strong
preference).
Treatment attitudes
Valuations for each of the two treatment options are
asked on a 10-point scale ranging from 1 (very bad) to
10 (excellent). Satisfaction with the received treatment
and with the physical and emotional effect of treatment
is measured on a 6-point scale from 1 (dissatisfied) to 6
(very satisfied). Patient’s attitudes towards striving for
length (quantity) or quality of life are assessed with 8
items by the ‘QQ Questionnaire’ [29]. High scores on
the quantity or quality scale indicate the importance of
length and quality of life, respectively.
Substitute judgment
When the medical oncologist informs patients about
this study, he or she is asked to judge whether or not
the patient will desire information about adverse events,
tumour response, and median survival that will be
offered in the interview.
Sample size calculation
Our primary research question is whether or not
patients want to be informed. For study question 1a,
about 100 patients in the intervention group will suffice
to estimate an assumed desire rate for prognostic infor-
mation of 80% with 95% confidence interval from 71%
to 87%. For study question 1b, regarding factors that
determine information desire, again about 100 patients
will suffice to detect a weak correlation of 0.28 between
a predictor and information desire, with a = 0.05 and a
power equal to 0.82. For question 2, dealing with the
ability of the medical oncologist to judge whether or not
the patient wants this information, the same analysis
applies as for study question 1b. For study question 3,
which addresses the effect of the introduction of deci-
sion support compared to usual care on patient well-
being, the intervention group is compared to the usual
care group. Because one of the main concerns of physi-
cians is that information on prognosis provokes anxiety,
anxiety is used as the main outcome measure. We
assume that the HADS anxiety difference between the
two groups at t3 is equal to 2.2, and the correlation
between the measurements at t1 and t3 equals 0.72. The
standard deviation in each cell is about 6, corresponding
to a medium sized effect size of 0.36. With a =0 . 0 5 ,
and 70 patients in each group, the power to detect the
assumed effect is equal to 0.81. In conclusion, 100
patients in the intervention group and 70 patients in the
usual care group suffice to answer the above research
questions. Assuming that 30% of the patients refuse to
give informed consent, and that 1% of patients has died
at t3, 246 patients will have to be approached.
Statistical Analysis
In all the analyses, scale values will be calculated only if
at least half of the items are available, by imputing the
mean of the available items. Question 1a about the
information desire will be answered by calculating the
desire rate for prognostic information with a 95% confi-
dence interval. For question 1b, which factors determine
information desire, patients will be grouped according
to information desire, ranging from 0 (no information
desired) to 3 (information on serious adverse events,
tumour response, and survival desired). Then compari-
sons between these four groups will be made. For cate-
gorical variables, the Chi-square test will be used.
Continuous data will also be analyzed using the Chi-
Square test, after a median-split subdivision into two
categories. The HADS scores will be divided by use of a
clinical cut-off point of 8 [17,30,31]. Bivariate analyses
will be presented with p-value of variables related with
information desire at the level of p < 0.2. Finally, these
variables will be entered simultaneously in a regression
model.
For question 2, agreement between the substitute
judgment of the oncologist and the patient information
desire is determined. Agreement can arise from chance;
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tistic, ranging from 0 to 1. A  of 0.2, 0.5, and 0.8 indi-
cates poor, moderate, and good agreement, respectively
[32,33]. In bivariate and multivariate analyses, associa-
tions will be sought between agreement and patient
variables (sociodemographic, medical, psychological,
knowledge and information). Dichotomized variables
associated with agreement at a level of p < 0.2 will be
entered simultaneously in a regression model.
Question 3, which addresses the effect of the intro-
duction of decision support compared to usual care on
patient well-being, will be answered by comparing the
intervention group with the usual care group. Analyses
of covariance corrected for differences at baseline are
used to test the effect of the intervention. For group
comparisons at a single point in time, a t test will be
performed for continuous variables and the Chi-square
test for categorical variables.
Ethical considerations
Ethical approval for the study is obtained from the
regional ethics review committee (CMO Arnhem-Nijme-
gen) and from the research ethics committees of all par-
ticipating hospitals. All participating patients will sign
an informed consent form.
Discussion
This study attempts to settle the debate on the desirabil-
ity of informing patients with cancer. To this end, the
amount of information desired by patients with
advanced cancer is investigated by offering information
in a decision aid. Furthermore, the study will show
whether it is possible to predict the amount of informa-
tion desired, either by patient and disease-related fac-
tors, or by judgment of the medical oncologist.
Concerns that the information may provoke patient
anxiety are addressed by evaluating the effects of the
decision aid using a randomized controlled design.
The study design has some limitations. Selection bias
could be introduced when oncologists select patients
who are more open to information or are in a better
psychological state. When the data collection is com-
pleted, the role of selection bias can be investigated by
comparing the resulting sample to other study samples,
and comparing patient characteristics between physi-
cians that included few versus many patients. Selective
patient participation based on patients’ information
desire is addressed by informing eligible patients about
the study in a general way, not mentioning the provision
of (prognostic) information.
Patients have to fill in a baseline questionnaire that
includes predictors for information desire and a baseline
measurement for the effect of the information. There-
fore, it is not feasible to include patients at the moment
of the treatment choice; pati e n t sh a v et ob ei n c l u d e d
during first-line chemotherapy. This timing may posi-
tively affect the inclusion rate, since patients will be less
distressed during first-line chemotherapy than at the
moment of disease progression. On the other hand, due
to the interval between the baseline questionnaire and
the interview, the association between information
desire and predictors may be weakened. In addition, the
correlation between the effect measures at baseline (t1)
and follow-up (t2 and t3) may be weakened.
Randomization is, for practical reasons, performed by
using sealed envelopes. In some of the 11 participating
h o s p i t a l s ,t h e r ew i l lb el i t t l et i m eb e t w e e nt h ed i a g n o s i s
of disease progression and subsequent consultation with
a nurse. Therefore, instant randomization will be
required and envelopes are a very practical method to
perform this. The use of envelopes leaves a possibility to
subvert the randomization procedure. However, a plain
attempt to allocate a patient out of sequence will be dis-
covered because the envelopes are sequentially num-
bered and the allocation can be compared with the
predetermined sequence. The oncologist could also
decide not to randomize a patient, but this would not
go unnoticed since all patients are registered on the trial
before the moment of randomization, therefore we will
be able to compare patients who were and were not
randomized.
Blinding of the medical oncologists and the patients is
not feasible in this type of research, because patients
may want to discuss the information from the decision
aid with their oncologist. However, patients are blinded
to the intervention in that they are not aware of the
exact content of the decision aid; they are only informed
that a new method of information giving is investigated.
A major strength of this study is that, in contrast to
many previous studies, we will actually deliver informa-
tion on treatment options to patients at the point of
decision making. The results of this study can be
applied to improve the provision of information in daily
clinical practice. Generalization to the target population
is facilitated by the broad inclusion criteria that are used
in this study and the use of the decision aid by various
nurses in the 11 participating hospitals. Furthermore,
the method used to assess patients’ information desire
very much resembles information giving in clinical prac-
tice, by actually providing information at the moment of
the treatment choice.
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